Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04805593 · ClinicalTrials.gov registry record · NA

Clinical Investigation of the WaveLight® EX500 Excimer Laser

A NA study of Hyperopia and Hyperopic Astigmatism, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
44
Enrollment target
5
Study locations

NCT04805593 is a NA study of Hyperopia and Hyperopic Astigmatism that has completed, run by Alcon Research. The registered enrollment target is 44 participants, below the 120-participant average among 10 other Hyperopia trials with a reported enrollment target (63% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04805593, a NA study of Hyperopia and Hyperopic Astigmatism, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to collect efficacy and safety data on the WaveLight EX500 excimer laser system for the correction of hyperopia with and without astigmatism by laser in situ keratomileusis (LASIK) treatment.

Interventions

  • PROCEDURE LASIK
  • DEVICE WaveLight EX500 excimer laser system

Study Locations (5)

Kansas

  • Durrie Vision - Overland Park

Missouri

  • Moyes Eye Center - Kansas City

North Carolina

  • Physicians Protocol - Greensboro

North Dakota

  • Vance Thompson Vision ND - West Fargo

Texas

  • Mann Eye Institute - Houston

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2021-04-28
Est. Completion 2023-05-02
Phase NA

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT04805593

The ClinicalTrials.gov registry entry for NCT04805593 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 10 other Hyperopia trials with a reported enrollment target (63% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hyperopia appearing as the primary indexed condition, and to 2 interventions - of which LASIK is the first listed.

NCT04805593 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Kansas, Missouri, North Carolina.

Frequently Asked Questions

What is clinical trial NCT04805593 about?

NCT04805593 is a clinical study titled "Clinical Investigation of the WaveLight® EX500 Excimer Laser". The purpose of this study is to collect efficacy and safety data on the WaveLight EX500 excimer laser system for the correction of hyperopia with and without astigmatism by laser in situ keratomileusis (LASIK) treatment.

What is the current status of trial NCT04805593?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2021-04-28. Estimated completion is 2023-05-02.

What conditions does trial NCT04805593 study?

This clinical trial studies the following conditions: Hyperopia, Hyperopic Astigmatism.

What interventions are being tested in trial NCT04805593?

The interventions under investigation include: LASIK (PROCEDURE), WaveLight EX500 excimer laser system (DEVICE).

Who is sponsoring clinical trial NCT04805593?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04805593 being conducted?

This trial has 5 study locations across Kansas, Missouri, North Carolina, North Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.